ShareProphets : keywords

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – France AxisBiotix-Ps regulatory approval, a commercialisation strategy continuing STRONG BUY

SkinBioTherapeutics (SBTX) has announced that it has received regulatory approval to sell its food supplement to alleviate the symptoms associated with psoriasis, AxisBiotix-Ps, into the French market and that marketing of the product there is expected to launch next month.

Subscribe to ShareProphets to access Premium Content

By HotStockRockets
6 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – no-one watching o’clock results and equity raise, what’s the outlook from here?

SkinBioTherapeutics (SBTX) has announced no-one watching o’clock (4:30pm) results for its year ended 30^th June 2022, with CEO Stuart Ashman stating “this financial year has been a mixed one for the group”. With the results coming with a potentially £3.5 million equity raise (albeit including an up to £1 million “retail offer”) at 16p per share, we’ve got some other words for it but where does this all leave the company now?

Subscribe to ShareProphets to access Premium Content

By Tom Winnifrith & Steve Moore
285 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – interim numbers & warning of slight delay largely irrelevant, the clear potential remains - Buy

SkinBioTherapeutics (SBTX) has announced results for its half-year ended 31^st December 2021 which show revenue of just £21,949, cash £1.5 million lower to £3.2 million and include a warning that full-year forecasts will be materially missed – and the shares have responded down to 35p. But here’s why we retain significant confidence and see this as a buying opportunity. From here this could be a 10 bagger.

Subscribe to ShareProphets to access Premium Content

By Tom Winnifrith & Steve Moore
546 days ago

SBTX

PREMIUM CONTENT

SkinBioTherapeutics – ‘Business Update’, high margin profit potential moving materially closer

SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30^th June year-end cash totalled £4.6 million. Sounds good.